Related Experiment Video

Updated: Jun 3, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

High dose methotrexate treatment in children with acute lymphoblastic leukaemia may be optimised by a weight-based

Peter Jönsson1, Tor Skärby, Jesper Heldrup

  • 1Department of Clinical Chemistry and Pharmacology, Lund University Hospital, Lund, Sweden. peter.g.jonsson@gmail.com

Pediatric Blood & Cancer
|March 23, 2011
PubMed

Insights

Dosing high-dose methotrexate (HDMTX) for acute lymphoblastic leukemia (ALL) needs individualization. Dosing based on body weight may improve pharmacokinetic predictability and patient outcomes in children with ALL.

Area of Science:

  • Pharmacokinetics and pharmacodynamics
  • Pediatric oncology
  • Drug metabolism and disposition

Background:

  • High-dose methotrexate (HDMTX) administration shows significant inter-individual variability in exposure.
  • Both under- and over-exposure to HDMTX can lead to severe adverse events.
  • Individualized dosing is crucial for optimizing HDMTX therapy.

Purpose of the Study:

  • To investigate the relationship between pharmacokinetic parameters and treatment outcomes in pediatric patients with acute lymphoblastic leukemia (ALL).
  • To identify patient-specific factors that influence HDMTX pharmacokinetics and clinical outcomes.
  • To evaluate the effectiveness of body weight-based dosing for HDMTX in children with ALL.

Main Methods:

  • A population pharmacokinetic model was developed using data from 1284 HDMTX courses in 304 children with ALL.
  • Patient characteristics including age, height, weight, body surface area (BSA), sex, serum creatinine, and serum alanine aminotransferase were assessed as covariates.
  • Logistic regression analysis was used to correlate pharmacokinetic parameters and patient factors with relapse risk and overall outcome.

Main Results:

  • Body weight was identified as the most significant covariate for improving the pharmacokinetic model, suggesting its utility for dose normalization.
  • Higher clearance and volume of distribution values were associated with an increased risk of relapse in standard and intermediate-risk ALL groups.
  • Increased body weight was strongly correlated with worse outcomes in the standard and intermediate-risk ALL patient groups.

Conclusions:

  • Dose normalization of HDMTX based on body weight may lead to more predictable pharmacokinetic profiles.
  • Adjusting HDMTX dosage according to body weight has the potential to improve treatment outcomes for children diagnosed with ALL.
  • Body weight-based dosing represents a promising strategy for optimizing HDMTX therapy in pediatric ALL patients.
Abstract

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...